Share Price and Basic Stock Data
Last Updated: December 30, 2025, 2:43 am
| PEG Ratio | 1.09 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genesys International Corporation Ltd operates within the IT Consulting & Software industry and has demonstrated significant revenue growth over the past few years. For the financial year ending March 2025, the company reported sales of ₹311 Cr, a substantial increase from ₹181 Cr in March 2023. Quarterly sales figures also reflect this upward trend, with the most recent quarter (June 2025) recording sales of ₹70.87 Cr. This consistent growth trajectory indicates a robust market demand for the company’s services. The trailing twelve months (TTM) sales stood at ₹331 Cr, showcasing a solid performance compared to previous years. The company has effectively leveraged its operational capabilities, as indicated by a notable increase in sales from ₹42.69 Cr in June 2022 to ₹94.16 Cr in March 2025. Overall, Genesys International’s revenue trends suggest a positive outlook in its operational effectiveness and market positioning.
Profitability and Efficiency Metrics
Genesys International’s profitability metrics highlight a strong operational performance, especially in the recent quarters. The operating profit margin (OPM) stood at an impressive 41.63%, indicating effective cost management and operational efficiency. The net profit for the financial year ending March 2025 was ₹56 Cr, significantly up from ₹15 Cr in March 2023, showcasing a robust recovery and growth in profitability. The return on equity (ROE) at 10.8% and return on capital employed (ROCE) at 15% further illustrate the company’s ability to generate returns from its equity and capital. However, the cash conversion cycle (CCC) of 261 days suggests a longer duration for converting investments into cash flow, which could be an area of concern. In summary, while profitability shows a positive trend, the efficiency metrics indicate potential room for improvement in cash flow management.
Balance Sheet Strength and Financial Ratios
Genesys International’s balance sheet reflects a solid financial position, with total assets reported at ₹778 Cr as of March 2025. The company maintains a conservative borrowing strategy, with total borrowings amounting to ₹147 Cr, resulting in a low total debt-to-equity ratio of 0.19. This low leverage indicates that the company is not overly reliant on debt for its operations, thereby reducing financial risk. The interest coverage ratio (ICR) of 16.68x signifies that the company comfortably meets its interest obligations. Additionally, the book value per share has increased to ₹139.53, compared to ₹107.93 in the previous year, indicating a strengthening of shareholder equity. However, the high price-to-book value (P/BV) ratio of 5.16x may suggest that the stock is priced at a premium relative to its book value, which could raise concerns among potential investors about valuation levels.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genesys International indicates a diverse ownership structure, with public shareholders holding 62.27% as of September 2025. Promoters own 31.55% of the company, which reflects a stable management control. However, foreign institutional investors (FIIs) have reduced their stake to 4.69%, down from 6.63% in December 2022, which may signal a decline in foreign investor confidence. Domestic institutional investors (DIIs) hold a modest 1.47%, indicating limited institutional interest. The total number of shareholders has grown significantly, reaching 45,192, reflecting increasing retail investor engagement. This diversification in ownership suggests potential resilience in the company’s stock performance, although the declining FII stake could warrant further scrutiny regarding international perceptions of the company’s growth prospects.
Outlook, Risks, and Final Insight
Looking ahead, Genesys International is well-positioned to capitalize on its operational strengths and market opportunities. The anticipated increase in sales and profitability could enhance its competitive edge in the IT consulting sector. However, risks remain, including the prolonged cash conversion cycle, which could impact liquidity and operational flexibility. Additionally, the reduction in foreign institutional investment raises concerns about potential volatility in the stock price. The company’s ability to manage its debt levels and maintain profitability will be crucial in navigating market challenges. In conclusion, while Genesys International has shown commendable growth and financial stability, careful attention to liquidity management and investor sentiment will be vital for sustaining its upward trajectory in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Visesh Infotecnics Ltd | 125 Cr. | 0.33 | / | 1.11 | 0.00 % | 2.21 % | 2.23 % | 1.00 | |
| Mudunuru Ltd | 55.1 Cr. | 17.4 | 17.4/4.43 | 0.20 | 0.00 % | 27.0 % | 90.7 % | 2.00 | |
| Naapbooks Ltd | 150 Cr. | 140 | 194/99.8 | 23.0 | 36.4 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 34.2 Cr. | 267 | 310/140 | 24.4 | 26.7 | 0.37 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 5.77 Cr. | 1.07 | 1.73/0.91 | 2.47 | 0.00 % | 2.14 % | 2.15 % | 2.00 | |
| Industry Average | 20,153.07 Cr | 548.08 | 86.41 | 123.78 | 0.55% | 14.88% | 20.92% | 6.84 |
All Competitor Stocks of Genesys International Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.69 | 37.38 | 54.43 | 46.62 | 34.55 | 33.19 | 59.34 | 71.17 | 55.76 | 72.02 | 89.09 | 94.16 | 70.87 |
| Expenses | 30.95 | 26.42 | 35.07 | 30.30 | 28.75 | 25.49 | 28.56 | 34.92 | 35.35 | 42.64 | 46.52 | 44.39 | 41.37 |
| Operating Profit | 11.74 | 10.96 | 19.36 | 16.32 | 5.80 | 7.70 | 30.78 | 36.25 | 20.41 | 29.38 | 42.57 | 49.77 | 29.50 |
| OPM % | 27.50% | 29.32% | 35.57% | 35.01% | 16.79% | 23.20% | 51.87% | 50.93% | 36.60% | 40.79% | 47.78% | 52.86% | 41.63% |
| Other Income | 1.37 | 1.93 | 1.79 | 1.41 | 0.93 | 1.11 | 2.53 | 0.46 | 1.41 | 1.00 | 1.84 | 0.11 | 1.27 |
| Interest | 0.54 | 0.56 | 0.35 | 1.22 | 0.67 | 0.72 | 1.09 | 1.43 | 1.24 | 1.88 | 2.58 | 3.08 | 3.18 |
| Depreciation | 8.14 | 8.90 | 9.30 | 10.86 | 11.30 | 10.94 | 11.06 | 11.18 | 11.80 | 12.25 | 15.69 | 15.29 | 15.43 |
| Profit before tax | 4.43 | 3.43 | 11.50 | 5.65 | -5.24 | -2.85 | 21.16 | 24.10 | 8.78 | 16.25 | 26.14 | 31.51 | 12.16 |
| Tax % | 55.53% | 5.83% | 32.70% | 64.42% | 4.39% | 20.70% | 25.71% | 38.63% | 39.64% | 31.69% | 20.73% | 39.73% | 42.60% |
| Net Profit | 1.97 | 3.23 | 7.73 | 2.00 | -5.46 | -3.43 | 15.73 | 14.79 | 5.30 | 11.09 | 20.71 | 19.00 | 6.98 |
| EPS in Rs | 1.36 | 1.30 | 2.13 | 0.57 | -1.41 | -0.87 | 4.19 | 3.76 | 1.36 | 2.83 | 5.20 | 4.76 | 1.71 |
Last Updated: August 20, 2025, 10:30 am
Below is a detailed analysis of the quarterly data for Genesys International Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 70.87 Cr.. The value appears to be declining and may need further review. It has decreased from 94.16 Cr. (Mar 2025) to 70.87 Cr., marking a decrease of 23.29 Cr..
- For Expenses, as of Jun 2025, the value is 41.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 44.39 Cr. (Mar 2025) to 41.37 Cr., marking a decrease of 3.02 Cr..
- For Operating Profit, as of Jun 2025, the value is 29.50 Cr.. The value appears to be declining and may need further review. It has decreased from 49.77 Cr. (Mar 2025) to 29.50 Cr., marking a decrease of 20.27 Cr..
- For OPM %, as of Jun 2025, the value is 41.63%. The value appears to be declining and may need further review. It has decreased from 52.86% (Mar 2025) to 41.63%, marking a decrease of 11.23%.
- For Other Income, as of Jun 2025, the value is 1.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Mar 2025) to 1.27 Cr., marking an increase of 1.16 Cr..
- For Interest, as of Jun 2025, the value is 3.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.08 Cr. (Mar 2025) to 3.18 Cr., marking an increase of 0.10 Cr..
- For Depreciation, as of Jun 2025, the value is 15.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.29 Cr. (Mar 2025) to 15.43 Cr., marking an increase of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.16 Cr.. The value appears to be declining and may need further review. It has decreased from 31.51 Cr. (Mar 2025) to 12.16 Cr., marking a decrease of 19.35 Cr..
- For Tax %, as of Jun 2025, the value is 42.60%. The value appears to be increasing, which may not be favorable. It has increased from 39.73% (Mar 2025) to 42.60%, marking an increase of 2.87%.
- For Net Profit, as of Jun 2025, the value is 6.98 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 6.98 Cr., marking a decrease of 12.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.71. The value appears to be declining and may need further review. It has decreased from 4.76 (Mar 2025) to 1.71, marking a decrease of 3.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:20 am
| Metric | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 60 | 47 | 64 | 114 | 115 | 112 | 80 | 120 | 181 | 198 | 311 | 331 |
| Expenses | 42 | 47 | 40 | 48 | 78 | 96 | 98 | 81 | 92 | 122 | 117 | 168 | 179 |
| Operating Profit | 53 | 13 | 7 | 16 | 36 | 19 | 13 | -2 | 28 | 59 | 81 | 143 | 152 |
| OPM % | 56% | 21% | 16% | 25% | 32% | 17% | 12% | -2% | 23% | 32% | 41% | 46% | 46% |
| Other Income | -1 | 2 | 6 | 3 | 4 | 3 | 4 | -30 | -42 | 6 | 5 | 4 | 7 |
| Interest | 0 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 5 | 10 | 12 |
| Depreciation | 7 | 8 | 7 | 13 | 14 | 19 | 21 | 19 | 19 | 37 | 44 | 55 | 62 |
| Profit before tax | 45 | 5 | 5 | 5 | 24 | 0 | -7 | -54 | -36 | 25 | 37 | 83 | 85 |
| Tax % | -1% | 11% | 6% | -41% | 28% | 1,108% | -23% | -5% | 11% | 40% | 42% | 32% | |
| Net Profit | 46 | 4 | 2 | 6 | 17 | -4 | -5 | -52 | -40 | 15 | 22 | 56 | 59 |
| EPS in Rs | 15.42 | 1.43 | 0.73 | 2.11 | 5.50 | 1.73 | 0.61 | -13.75 | 4.28 | 5.05 | 5.58 | 14.12 | 14.55 |
| Dividend Payout % | 8% | 9% | 17% | 6% | 2% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 183.33% | -123.53% | -25.00% | -940.00% | 23.08% | 137.50% | 46.67% | 154.55% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | -16.67% | -306.86% | 98.53% | -915.00% | 963.08% | 114.42% | -90.83% | 107.88% |
Genesys International Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 38% |
| TTM: | 49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 98% |
| 3 Years: | -3% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 63% |
| 3 Years: | 1% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 4:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:16 am
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 19 | 20 | 20 | 21 |
| Reserves | 126 | 193 | 195 | 152 | 209 | 208 | 197 | 158 | 189 | 387 | 469 | 536 | 662 |
| Borrowings | 2 | 12 | 14 | 22 | 24 | 26 | 16 | 14 | 26 | 39 | 60 | 122 | 147 |
| Other Liabilities | 23 | 25 | 37 | 135 | 136 | 134 | 136 | 117 | 88 | 61 | 86 | 100 | 90 |
| Total Liabilities | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 | 920 |
| Fixed Assets | 46 | 21 | 22 | 179 | 217 | 208 | 203 | 194 | 138 | 157 | 156 | 128 | 265 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 65 | 113 | 156 | 4 |
| Investments | 8 | 122 | 156 | 25 | 11 | 11 | 15 | 8 | 6 | 51 | 0 | 0 | 0 |
| Other Assets | 111 | 101 | 84 | 120 | 157 | 165 | 147 | 102 | 156 | 232 | 366 | 495 | 652 |
| Total Assets | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 | 920 |
Below is a detailed analysis of the balance sheet data for Genesys International Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Mar 2025) to 21.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 662.00 Cr.. The value appears strong and on an upward trend. It has increased from 536.00 Cr. (Mar 2025) to 662.00 Cr., marking an increase of 126.00 Cr..
- For Borrowings, as of Sep 2025, the value is 147.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 122.00 Cr. (Mar 2025) to 147.00 Cr., marking an increase of 25.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 90.00 Cr.. The value appears to be improving (decreasing). It has decreased from 100.00 Cr. (Mar 2025) to 90.00 Cr., marking a decrease of 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 920.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 778.00 Cr. (Mar 2025) to 920.00 Cr., marking an increase of 142.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 265.00 Cr.. The value appears strong and on an upward trend. It has increased from 128.00 Cr. (Mar 2025) to 265.00 Cr., marking an increase of 137.00 Cr..
- For CWIP, as of Sep 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 152.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 652.00 Cr.. The value appears strong and on an upward trend. It has increased from 495.00 Cr. (Mar 2025) to 652.00 Cr., marking an increase of 157.00 Cr..
- For Total Assets, as of Sep 2025, the value is 920.00 Cr.. The value appears strong and on an upward trend. It has increased from 778.00 Cr. (Mar 2025) to 920.00 Cr., marking an increase of 142.00 Cr..
Notably, the Reserves (662.00 Cr.) exceed the Borrowings (147.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 51.00 | 1.00 | -7.00 | -6.00 | 12.00 | -7.00 | -3.00 | -16.00 | 2.00 | 20.00 | 21.00 | 21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Working Capital Days | 172 | 326 | 172 | 105 | 99 | 215 | 223 | 126 | 82 | 212 | 269 | 291 |
| ROCE % | 41% | 3% | 3% | 8% | 1% | -1% | -7% | 4% | 7% | 8% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 14.17 | 5.78 | 5.44 | 4.28 | -13.77 |
| Diluted EPS (Rs.) | 14.06 | 5.74 | 5.29 | 4.28 | -13.34 |
| Cash EPS (Rs.) | 27.92 | 16.72 | 13.81 | -6.55 | -10.57 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 139.53 | 123.71 | 107.93 | 75.21 | 81.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 139.53 | 123.71 | 107.93 | 75.21 | 81.64 |
| Revenue From Operations / Share (Rs.) | 78.14 | 50.14 | 47.97 | 38.14 | 25.48 |
| PBDIT / Share (Rs.) | 36.80 | 21.64 | 17.18 | 9.83 | -0.49 |
| PBIT / Share (Rs.) | 22.98 | 10.39 | 7.33 | 3.74 | -6.51 |
| PBT / Share (Rs.) | 20.77 | 9.40 | 6.62 | -11.44 | -17.43 |
| Net Profit / Share (Rs.) | 14.10 | 5.47 | 3.95 | -12.65 | -16.59 |
| NP After MI And SOA / Share (Rs.) | 14.13 | 5.58 | 5.05 | 4.28 | -13.75 |
| PBDIT Margin (%) | 47.09 | 43.16 | 35.81 | 25.78 | -1.95 |
| PBIT Margin (%) | 29.40 | 20.72 | 15.27 | 9.79 | -25.53 |
| PBT Margin (%) | 26.58 | 18.75 | 13.79 | -29.98 | -68.43 |
| Net Profit Margin (%) | 18.03 | 10.90 | 8.24 | -33.17 | -65.09 |
| NP After MI And SOA Margin (%) | 18.07 | 11.13 | 10.53 | 11.21 | -53.96 |
| Return on Networth / Equity (%) | 10.12 | 4.51 | 4.70 | 6.54 | -24.77 |
| Return on Capital Employeed (%) | 15.53 | 7.81 | 6.33 | 4.76 | -7.59 |
| Return On Assets (%) | 7.22 | 3.47 | 3.77 | 4.17 | -14.11 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.04 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.10 | 0.07 | 0.09 | 0.03 |
| Asset Turnover Ratio (%) | 0.44 | 0.34 | 0.43 | 0.41 | 0.23 |
| Current Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Quick Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Interest Coverage Ratio (X) | 16.68 | 21.89 | 24.33 | 12.45 | -0.53 |
| Interest Coverage Ratio (Post Tax) (X) | 7.39 | 6.53 | 6.60 | 3.19 | -6.06 |
| Enterprise Value (Cr.) | 2956.65 | 2312.97 | 1258.23 | 1817.61 | 404.10 |
| EV / Net Operating Revenue (X) | 9.51 | 11.67 | 6.95 | 15.19 | 5.08 |
| EV / EBITDA (X) | 20.18 | 27.03 | 19.40 | 58.93 | -260.36 |
| MarketCap / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| Price / BV (X) | 5.16 | 4.78 | 3.06 | 8.73 | 1.84 |
| Price / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.13 |
After reviewing the key financial ratios for Genesys International Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 14.17. This value is within the healthy range. It has increased from 5.78 (Mar 24) to 14.17, marking an increase of 8.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is 14.06. This value is within the healthy range. It has increased from 5.74 (Mar 24) to 14.06, marking an increase of 8.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.92. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 27.92, marking an increase of 11.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.53. It has increased from 123.71 (Mar 24) to 139.53, marking an increase of 15.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.53. It has increased from 123.71 (Mar 24) to 139.53, marking an increase of 15.82.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 78.14. It has increased from 50.14 (Mar 24) to 78.14, marking an increase of 28.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.80. This value is within the healthy range. It has increased from 21.64 (Mar 24) to 36.80, marking an increase of 15.16.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.98. This value is within the healthy range. It has increased from 10.39 (Mar 24) to 22.98, marking an increase of 12.59.
- For PBT / Share (Rs.), as of Mar 25, the value is 20.77. This value is within the healthy range. It has increased from 9.40 (Mar 24) to 20.77, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 14.10. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 14.10, marking an increase of 8.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 14.13. This value is within the healthy range. It has increased from 5.58 (Mar 24) to 14.13, marking an increase of 8.55.
- For PBDIT Margin (%), as of Mar 25, the value is 47.09. This value is within the healthy range. It has increased from 43.16 (Mar 24) to 47.09, marking an increase of 3.93.
- For PBIT Margin (%), as of Mar 25, the value is 29.40. This value exceeds the healthy maximum of 20. It has increased from 20.72 (Mar 24) to 29.40, marking an increase of 8.68.
- For PBT Margin (%), as of Mar 25, the value is 26.58. This value is within the healthy range. It has increased from 18.75 (Mar 24) to 26.58, marking an increase of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 18.03. This value exceeds the healthy maximum of 10. It has increased from 10.90 (Mar 24) to 18.03, marking an increase of 7.13.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has increased from 11.13 (Mar 24) to 18.07, marking an increase of 6.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.12. This value is below the healthy minimum of 15. It has increased from 4.51 (Mar 24) to 10.12, marking an increase of 5.61.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.53. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 15.53, marking an increase of 7.72.
- For Return On Assets (%), as of Mar 25, the value is 7.22. This value is within the healthy range. It has increased from 3.47 (Mar 24) to 7.22, marking an increase of 3.75.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.19, marking an increase of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.34 (Mar 24) to 0.44, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Quick Ratio (X), as of Mar 25, the value is 2.41. This value exceeds the healthy maximum of 2. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 16.68. This value is within the healthy range. It has decreased from 21.89 (Mar 24) to 16.68, marking a decrease of 5.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.39. This value is within the healthy range. It has increased from 6.53 (Mar 24) to 7.39, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,956.65. It has increased from 2,312.97 (Mar 24) to 2,956.65, marking an increase of 643.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has decreased from 11.67 (Mar 24) to 9.51, marking a decrease of 2.16.
- For EV / EBITDA (X), as of Mar 25, the value is 20.18. This value exceeds the healthy maximum of 15. It has decreased from 27.03 (Mar 24) to 20.18, marking a decrease of 6.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 4.78 (Mar 24) to 5.16, marking an increase of 0.38.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesys International Corporation Ltd:
- Net Profit Margin: 18.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.53% (Industry Average ROCE: 14.88%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.12% (Industry Average ROE: 20.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.39
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.3 (Industry average Stock P/E: 86.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | 73-A, SDF-III, SEEPZ, Mumbai Maharashtra 400096 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sajid Malik | Chairman & Managing Director |
| Ms. Bharti Sinha | Independent Director |
| Mr. Manish Patel | Independent Director |
| Mr. Ajay Aggarwal | Independent Director |
| Mr. Omprakash Hemrajani | Director |
| Dr. Yogita Shukla | Director |
FAQ
What is the intrinsic value of Genesys International Corporation Ltd?
Genesys International Corporation Ltd's intrinsic value (as of 29 December 2025) is 437.93 which is 2.80% higher the current market price of 426.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,778 Cr. market cap, FY2025-2026 high/low of 1,055/390, reserves of ₹662 Cr, and liabilities of 920 Cr.
What is the Market Cap of Genesys International Corporation Ltd?
The Market Cap of Genesys International Corporation Ltd is 1,778 Cr..
What is the current Stock Price of Genesys International Corporation Ltd as on 29 December 2025?
The current stock price of Genesys International Corporation Ltd as on 29 December 2025 is 426.
What is the High / Low of Genesys International Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesys International Corporation Ltd stocks is 1,055/390.
What is the Stock P/E of Genesys International Corporation Ltd?
The Stock P/E of Genesys International Corporation Ltd is 30.3.
What is the Book Value of Genesys International Corporation Ltd?
The Book Value of Genesys International Corporation Ltd is 164.
What is the Dividend Yield of Genesys International Corporation Ltd?
The Dividend Yield of Genesys International Corporation Ltd is 0.00 %.
What is the ROCE of Genesys International Corporation Ltd?
The ROCE of Genesys International Corporation Ltd is 15.0 %.
What is the ROE of Genesys International Corporation Ltd?
The ROE of Genesys International Corporation Ltd is 10.8 %.
What is the Face Value of Genesys International Corporation Ltd?
The Face Value of Genesys International Corporation Ltd is 5.00.